PLRX COO has 6,917 shares sold to cover taxes

Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo had 6,917 shares of common stock sold on January 20, 2026 at a price of $1.28 per share.

Rhea-AI Filing Summary

Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo had 6,917 shares of common stock sold on January 20, 2026 at a price of $1.28 per share. This was a nondiscretionary sale by a plan under Rule 10b5-1, carried out by a broker as part of transactions at prices ranging from $1.245 to $1.33 between January 20 and January 22, 2026. The sales were made on behalf of a group of employees, including Kuo, to cover withholding taxes related to the vesting of previously granted restricted stock units. After this transaction, Kuo beneficially owned 37,806 shares of Pliant Therapeutics common stock directly.

Insider Trade Summary

Net Seller: 6,917 shares

Net Sell 1 txn

Insider Kuo Minnie

Role Chief Operating Officer

Sold 6,917 shs ($9K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,917	$1.28	$9K

Holdings After Transaction: Common Stock — 37,806 shares (Direct)

Footnotes (1)

1. F1. Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PLRX report for COO Minnie Kuo?

PLRX reported that Chief Operating Officer Minnie Kuo had 6,917 shares of common stock sold on January 20, 2026 in a transaction reported with code S (sale).

What was the sale price for the PLRX shares in Minnie Kuo’s Form 4?

The Form 4 lists a sale price of $1.28 per share for the 6,917 shares of Pliant Therapeutics common stock reported as sold.

Why were Minnie Kuo’s PLRX shares sold according to the Form 4 footnote?

The footnote explains the sale was a nondiscretionary sale by a plan under Rule 10b5-1 to pay withholding tax liabilities arising from the vesting of previously granted restricted stock units for a group of employees, including Kuo.

How many PLRX shares does Minnie Kuo own after the reported transaction?

Following the reported sale, Chief Operating Officer Minnie Kuo beneficially owned 37,806 shares of Pliant Therapeutics common stock, held directly.

Over what price range were PLRX shares sold under the plan described in the Form 4 footnote?

The footnote states that the broker sold shares for the employee group at prices ranging from $1.245 to $1.33 per share between January 20, 2026 and January 22, 2026, with $1.28 representing the weighted average for Kuo’s reported shares.

What is Minnie Kuo’s role at Pliant Therapeutics (PLRX) as disclosed in the Form 4?

The Form 4 identifies Minnie Kuo as an officer of Pliant Therapeutics, Inc., serving as the company’s Chief Operating Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/22/2026 - 09:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kuo Minnie

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		6,917	D	$1.28(1)	37,806	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.